鑒於專利處方藥品支出占社會所得的重大比率，各國政府無不致力找尋社會最適下的專利藥品處方市場政策。然傳統供需模型常著重於價格控制，可能導致非社會最適的結果，因此本篇文章依據過去文獻對於專利處方藥品市場的特性研究，引入最適控制機制(optimal control)，建立一個適用於專利處方藥品市場的完整動態模型，用以判斷目前專利處方藥品的市場政策是否正確，並提出適當的政策建議。

Pharmaceutical expenditures are one of the main voices in social expenditure balance sheets. Accordingly the pharmaceutical market is of major interest to policy makers. This paper argues that policies based on simple demand-supply models, which often result in price controls, are either inefficient or counterproductive. This thesis aims at developing a comprehensive dynamic model for the market of patented prescription drugs. Optimization will use a standard methodology used in replenishable resource management: optimal control. The predictions of the framework will be tested against the standing literature, used to assess current policy approaches and formulate alternatives.

Chapter One: Literature review 1
Introduction 1
1.1 Market peculiarities 3
1.2 Utility, expectations and information 6
1.3 The role of innovation and signaling 10
1.4 Equilibrium? 13
Chapter two: Theoretical model 14
2.1 An alternative perspective 14
2.2 General model 14
2.3 The cost of market opening 16
2.4 Patent expiry 21
2.5 The epidemic function 24
2.6 Long term dynamic equilibrium 26
Chapter Three: Comparative statics and assessment 35
3.1 Comparative statics 35
3.2 Current management policies: the case of price controls 40
3.3 Failure of mainstream approaches 45
3.4 Future policies implications 47
Conclusions 50
References 51

1. Achilladelis B and Antonakis N, “The. Dynamics of technological innovation: the case of the pharmaceutical industry”, Research Policy 2001;30: pages 535–542, 2001
2. Adams CP and Brantner VV, “Estimating The Cost Of New Drug Development: Is It Really $802 Million?”, Health Aff., 25: pages 2420-428 2006
3. Anderson JM, Byrne AA, Fields R, Segovia L and Swift RJ, “Some Simple Epidemic Models” California State Polytechnic University Pomona, Desectionment of Mathematics Technical Report, 2006+
4. Bailey NTJ, “The simple stochastic epidemic: A complete solution in terms of Known functions” Biometrika, 50: pages 235–240, 1963
5. Cardarelli R, Licciardone JC and Taylor LG, “A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: Is what they tell us important and true?”, BMC Family Practice, pages 7-13, 2006
6. Caves RE, Whinston MD and Hurwitz MA, “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry” Brookings Papers on Economic Activity. Vol. 1991, 1991
7. Cochrane JH, “Time-Consistent Health Insurance”, Journal of Political Economy, Vol. 103, No. 3, pages 445-473, 1995
8. Conrad JM, “Resource Economics”, Cornell University, Cambridge university press, New York, 1999
9. Cook A, “How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry”, Congress of the United States, Congressional Budget Office, 1998, chapter 3 †
10. Corey R, “Fear”, Milano: Universita Bocconi editore, 2005
11. Daley DJ and Gani J, “Epidemic Modelling: An Introduction”, Cambridge University Press, 1999
12. Danzon PM and Chao L-W, “Cross-national price differences for pharmaceuticals: how large and why?”, Journal of Health Economics, pages 159-95, 2000
13. Eakin BK, “Allocative Inefficiency in the Production of Hospital Services”, Southern Economic Journal Vol. 58, No. 1 pages 240-248 1991
14. Freeman C, “Long Wave Theory”, Edward Elgar Publ. Cheltenham. C. ŽEd, 1996
15. Gatica G, Papageorgiou LG and Shah N, “A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry”, Computers & Chemical Engineering, Volume 28, Issue 5, Pages 707–725, 2004
16. Grabowski H,Vernon J and DiMasi JA, “Returns on Research and Development for 1990s New Drug Introductions”, PharmacoEconomics, Volume 20, Issue 3 Supplement, pages 11-29, 2002
17. Hobbes T, “Leviathan”, New York: Cambridge University press, 1951
18. Maynard A and Bloor K, “Dilemmas In Regulation Of The Market For Pharmaceuticals”, Health Affairs, vol. 22 no. 3 pages 31-41, 2003
19. Mossialos E, “Pharmaceutical pricing, financing and cost containment in the European Union Member States”, in R. Leidl (ed.), Health Care and its Financing in the Single European Market, Amsterdam: IOS Press, 1998
20. Mossialos E, Mrazek M and Walley T, “Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity, And Quality”, McGraw-Hill International, 2004
21. Moynihan R, Heath L, and Henry D, “Selling sickness: the pharmaceutical industry and disease mongering”, BMJ, 324(7342): pages 886–891, 2002
22. Mrazek MF, “Comparative approaches to pharmaceutical price regulation in the European Union”, Croatian Medical Journal, 43 (4): pages 453–61, 2002
23. Munos B, “Lessons from 60 years of pharmaceutical innovation”, Nature Reviews Drug Discovery 8, pages 959-968, 2009
24. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos B, Lindborg SR and Schacht AL, “How to improve R&D productivity: the pharmaceutical industry's grand challenge”, Nature Reviews Drug Discovery 9, pages 203-214, 2010
25. Puig-Junoy J‡,“The Public Financing of Pharmaceuticals An Economic Approach”, Edward Elgar Publishing, Northampton, 2005
26. Rawlins MD, “Opinion: Cutting the cost of drug development?” Nature Reviews Drug Discovery 3, pages 360-364, April 2004
27. Roberts PW, “Product Innovation, Product market, Competition And Persistent Profitability In The U.S. Pharmaceutical Industry”, Strategic Management Journal, 20: pages 655-670, 1999
28. Rogers MJ, Gupta A, and Maranas CD, “Risk Management In Real Options Based Pharmaceutical Portfolio Planning”, Desectionment of Chemical Engineering, The Pennsylvania State University, University Park, Ind. Eng. Chem. Res. 2002, 41, pages 6607-6620
29. Svejgaard A, Jersild C, Nielsen LS and Bodmer WF, “HL-A Antigens and Disease Statistical and Genetical Considerations”, Volume 4, Issue 1, pages 95–105, 1974
30. Virts JR and Weston JF, “Returns to research and development in the us pharmaceutical industry”, Managerial and Decision Economics, Volume 1, Issue 3, pages 103–111, 1980
31. Windmeijer F, de Laat E and Douven R, “Pharmaceutical promotion and GP prescription behavior”, Health Economics, Vol. 15, Issue 1, pages 5–18, 2006
32. Wolf P, Brouwer WB and Rutten FF, “Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?”, The International Journal of Health Planning and Management, Volume 20, Issue 4, pages 351–374, 2005

+ Unpublished manuscript
† CBO study, not peer reviewed
‡ This is a collection of articles of different authors. Authors of articles used which differ in name from the editor will appear in the in-text citation followed by the editors name for index purposes